J&J has been rapidly building its portfolio in both medical technology and drug development to help prepare for the impending loss of exclusivity for Stelara, its top-selling drug for psoriasis, in the US next year.
J&J has been rapidly building its portfolio in both medical technology and drug development to help prepare for the impending loss of exclusivity for Stelara, its top-selling drug for psoriasis, in the US next year.
J&J slides as device margins droop, drug sales seen falling financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
(Bloomberg) Johnson & Johnson shares tumbled after the company said profit margins in its medical device and technology unit fell last quarter and drug sales will be lower in the second half of the year than the first.Most Read from BloombergChina Weighs Stock Market Rescue Package Backed by $278 BillionNetflix Pays $5 Billion for ‘Raw’ in Bet on Live EventsAn Isolated Israel Doubles Down on War in Gaza — At All CostsIndia Tops Hong Kong as World’s Fourth-Largest Stock MarketHong Kong Stocks